YOQNEAM, ISRAEL--(Marketwire - July 18, 2007) - Given Imaging Ltd. (NASDAQ: GIVN) today announced the results of its annual shareholders' meeting which was held today in Yoqneam, Israel. A total of 20,257,650 shares, or approximately 70% of the total number of shares entitled to vote at the meeting, were represented, and all nine of the proposed resolutions were approved.

The following resolutions were approved today:

1.  Israel Makov was elected to serve as a director and will now serve as
    Chairman of the Board of Directors. Dennert O. Ware and Arie
    Mientkavitch were also elected to serve as directors of the company.
    In addition, Doron Birger, Nachum "Homi" Shamir and Anat Leowenstein
    were all reelected as directors of the company until the next Annual
    General Meeting of Shareholders.

2.  Michael Grobstein and James Cornelius were elected as external
    directors of the company for a three-year term until December 2010.

3.  Changes to directors' compensation.

4.  Engagement terms of the Chairman of the Board of Directors.

5.  2007 compensation and amendments to the employment contract of the
    President and Chief Executive Officer of the Company.

6.  An increase in the number of ordinary shares reserved for issuance
    under the Company's 2006 Equity Incentive Plan.

7.  Registration rights agreement between the Company and certain holders
    of ordinary shares of the Company.

8.  An increased maximum coverage under the Company's directors' and
    officers' insurance.

9.  Somekh Chaikin, a member of KPMG International, was reappointed as the
    Company's independent auditor until the Company's next Annual General
    Meeting of Shareholders.  The Company's Audit Committee and Board of
    Directors were authorized to determine their remuneration.

The board of directors wishes to thank shareholders for participating and voting at this annual general meeting.

About Given Imaging Ltd.

Given Imaging is redefining gastrointestinal diagnosis by developing, producing and marketing innovative, patient-friendly products for detecting gastrointestinal disorders. The company's technology platform is the PillCam® Platform, featuring the PillCam video capsule, a disposable, miniature video camera contained in a capsule, which is ingested by the patient, a sensor array, data recorder and RAPID® software. Given Imaging has three commercially available capsules: the PillCam SB video capsule to visualize the entire small intestine which is currently marketed in the United States and in more than 60 other countries; the PillCam ESO video capsule to visualize the esophagus; and the Agile™ patency capsule to determine the free passage of the PillCam capsule in the GI tract. The PillCam COLON video capsule to visualize the colon has been cleared for marketing in the European Union, and multi-center clinical trials are underway in Europe and the U.S. A capsule to visualize the stomach is under development. More than 500,000 patients worldwide have benefited from the PillCam capsule endoscopy procedure. Given Imaging's headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel. It has operating subsidiary companies in the United States, Germany, France, Japan and Australia. For more information, visit http://www.givenimaging.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as "may," "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) satisfactory results of clinical trials with PillCam Colon (2) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (3) our success in implementing our sales, marketing and manufacturing plans, (4) protection and validity of patents and other intellectual property rights, (5) the impact of currency exchange rates, (6) the effect of competition by other companies, (7) the outcome of future litigation, including patent litigation with Olympus Corporation, (8) the reimbursement policies for our product from healthcare payors, (9) quarterly variations in operating results, (10) the possibility of armed conflict or civil or military unrest in Israel, and (11) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as "Risk Factors," "Cautionary Language Regarding Forward-Looking Statements" and "Operating Results and Financial Review and Prospects" in the Company's Annual Report on Form 20-F for the year ended December 31, 2006. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except for the Company's ongoing obligations to disclose material information under the applicable securities laws, it undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

Contact Information: For further information contact: Fern Lazar/David Carey Lazar Partners Ltd. 1-(866) GIVEN-IR